Annual report pursuant to Section 13 and 15(d)

Segment, Geographical and Other Revenue Information - Concentration Risk (Details)

v3.20.4
Segment, Geographical and Other Revenue Information - Concentration Risk (Details)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Merck | Revenue, Product and Service Benchmark      
Concentration Risk [Line Items]      
Concentration risk, percentage 26.00% 28.00% 29.00%
Merck | Accounts Receivable      
Concentration Risk [Line Items]      
Concentration risk, percentage 32.00% 38.00%  
Nestle Health Science | Revenue, Product and Service Benchmark      
Concentration Risk [Line Items]      
Concentration risk, percentage 11.00% 15.00% 22.00%
Nestle Health Science | Accounts Receivable      
Concentration Risk [Line Items]      
Concentration risk, percentage 13.00% 10.00%  
Novartis | Revenue, Product and Service Benchmark      
Concentration Risk [Line Items]      
Concentration risk, percentage   23.00%  
Novartis | Accounts Receivable      
Concentration Risk [Line Items]      
Concentration risk, percentage 25.00%    
Tate & Lyle | Revenue, Product and Service Benchmark      
Concentration Risk [Line Items]      
Concentration risk, percentage     13.00%
Takeda | Revenue, Product and Service Benchmark      
Concentration Risk [Line Items]      
Concentration risk, percentage 19.00%